Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy?

Eli Lilly reported third-quarter revenue of $24.4 billion, up 39% year over year, and EPS of $7.22, up 16%; management raised full-year revenue guidance from $85–87 billion to $91–92 billion. Zepbound sales rose 49% to about $5.4 billion and Mounjaro sales climbed 65% to more than $10.7 billion. The article argues Lilly could benefit from broader GLP-1 use and new indications, while noting shares already rose 57% in 52 weeks and trade at 47 times trailing earnings; potential addiction and anti-aging benefits remain preliminary, including evidence from mice.

Analysis

The investable question is not whether GLP-1s have more possible indications, but how much of that optionality is already embedded in LLY’s premium multiple. Near term, enthusiasm around oral access and coverage can support estimates; over 1–3 months, prescription persistence, net pricing, supply, and payer terms matter more than speculative indications. Broader coverage can expand volume while simultaneously increasing rebates and utilization controls, so headline market growth need not translate proportionally into profit growth.

Over 6–18 months, oral formulations and international expansion could enlarge the category, but also lower barriers to substitution and intensify price competition between LLY and NVO. Capacity, tolerability, adherence, and outcomes in controlled trials are the gating variables. Addiction and anti-aging are distant options, not a sound basis for current earnings assumptions: the cited longevity evidence is in mice, and clinical validation would take years. Any thesis that extrapolates it to tirzepatide is especially speculative.

LLY’s lead supports durable growth, but leaves less room for execution or reimbursement disappointment at a premium valuation. NVO may offer relative upside if oral adoption or evidence narrows the perceived competitive gap; this is not a claim that its economics are superior. MRK’s Keytruda position should not be treated as impaired by GLP-1 growth: the therapies address different markets. Falsify the category-growth thesis if prescription trends, net pricing, or guidance weaken; falsify the LLY premium thesis if sustained execution fails to support estimates.

Key Decisions for Investors

• Do not chase LLY solely on expanded-indication or anti-aging narratives. Wait for a pullback or evidence that prescription growth converts into durable net sales and earnings; reassess on guidance, payer coverage, and pricing updates.
• Consider a modest relative-value pair—long NVO / short LLY—only after checking current valuation, oral-product uptake, and supply capacity. The thesis is convergence in competitive expectations, not a short on GLP-1 demand; exit if LLY widens its lead in prescriptions or NVO execution disappoints.
• Track quarterly prescription trends, realized net pricing/rebates, manufacturing availability, and persistence by oral versus injectable users. Weakness in these measures would challenge both the growth narrative and premium multiples.
• Treat addiction and aging indications as watch items, not base-case catalysts. Upgrade their value only after human efficacy and safety data, regulatory pathways, and credible timelines emerge.